Literature review · Muscle & strength

Ipamorelin

Human research includes GH-response experiments and a postoperative bowel-function trial. Endocrine activity did not translate into a significant efficacy result in the selected surgical trial.

By HeartPep · Reviewed · 3 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Different study purposes need different conclusions: an acute GH response supports a pharmacology observation, while a clinical endpoint requires a suitable controlled trial.

Identity & scope

Ipamorelin is the named GH-releasing peptide and ghrelin-receptor agonist used in these studies. A compound name does not establish a supplier product’s composition or delivery.

Catalogue labels covered: Ipamorelin.

What the research shows

  • The pharmacokinetic study characterized the relationship between exposure and GH release.
  • The bowel-surgery trial provides an important negative efficacy result alongside the hormone literature.

Critical interpretation

Pharmacology and clinical efficacy answer different questions

The healthy-volunteer study characterises how ipamorelin exposure relates to a GH-release episode. The bowel-surgery trial instead asks whether a defined intervention improves a functional recovery measure. That trial did not show a significant meal-tolerance benefit. Its small proof-of-concept design does not exclude every possible effect, but it also cannot be cited as positive efficacy evidence. Reading the two papers together prevents a hormone response from standing in for a clinical result. [1] [2]

The nasal evidence has an explicit species boundary

The route-comparison study measured ipamorelin absorption in male rats. It helps identify a formulation question worth investigating, but does not establish human exposure. Differences in peptide, species and delivery preparation matter even within this small family of secretagogues. A human infusion experiment and a rat nasal experiment cannot be combined into a verified human nasal treatment effect. That would require evidence connecting the actual formulation to measured exposure and an appropriate outcome. [3]

Limitations & uncertainties

  • These studies do not establish improved muscle strength or exercise recovery.
  • Short clinical studies cannot establish the safety or effectiveness of another route or a commercial blend.

Open research questions

  • Which endpoint is the proposed research intended to measure?
  • Does a source test ipamorelin alone or a combination, and does its formulation match the material under investigation?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens in a new tab)

Gobburu JV, Agersø H, Jusko W, Ynddal L. (1999). Pharmaceutical Research. DOI: 10.1023/a:1018955126402 (opens in a new tab) · PMID 10496658

Design & population
Dose-escalation infusion experiment with eight healthy male volunteers at each of five exposure levels.
What the study found
A short GH-release episode followed ipamorelin exposure; the investigators developed a model relating drug concentration to GH response.
Limits on interpretation
A pharmacokinetic and hormone-response study, without a strength, body-composition or recovery efficacy endpoint.
Human studyNamed compoundAbstract / record checked

2. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (opens in a new tab)

Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). International Journal of Colorectal Disease. DOI: 10.1007/s00384-014-2030-8 (opens in a new tab) · PMID 25331030

Design & population
Multicentre double-blind placebo-controlled phase 2 trial after bowel surgery;117 patients enrolled,114 included in the safety and modified intention-to-treat populations.
What the study found
The key meal-tolerance endpoint and secondary efficacy analyses did not differ significantly from placebo.
Limits on interpretation
Small proof-of-concept study with diverse underlying surgical conditions. It cannot establish effectiveness for a different indication or catalogue formulation.
Animal studyNamed compoundAbstract / record checked

3. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption (opens in a new tab)

Johansen PB, Hansen KT, Andersen JV, Johansen NL. (1998). Xenobiotica. DOI: 10.1080/004982598238976 (opens in a new tab) · PMID 9879640

Design & population
Comparative pharmacokinetic experiment in male rats using different administration routes for ipamorelin and related peptides.
What the study found
The study measured nasal uptake of ipamorelin in rats and differences in clearance and excretion between peptides.
Limits on interpretation
Animal absorption data, not a human nasal efficacy study. Species, formulation and delivery differences prevent assigning this exposure result to a commercial spray.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov ipamorelin randomized postoperative ileus trial
  • site.pubmed.ncbi.nlm.nih.gov "9879640"
  • site.pubmed.ncbi.nlm.nih.gov "ipamorelin" "bioavailability"

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. Ipamorelin: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/ipamorelin.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes